Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form called the classic Fabry disease. This classic form mostly affects male. Symptoms of this disorder usually appear during childhood or adolescence in both male and female which includes pain that can be either full body or localized known as pricking sensation or numbness (acroparesthesia), gastro hyperactivity, burning sensation in hands, renal inefficiency, cardiac problem and cloudiness of cornea. The pain that is caused by the disease can be treated with anticonvulsants like phenytoin and carbamazepine. Gastric hyperactivity is treated by metoclopramide. Some patient may require dialysis or kidney replacement. However, restricting diet does not help to reduce lipid buildup in cells. The incidence of Fabry disease affects approximately 1 in 40,000 to 60,000 males. Occurrence of this disorder is less frequent in females.
Fabry disease market can be segmented on the basis of its treatment and geography. The type of treatment can be classified as Enzyme replacement therapy (ERT), Alternative therapies and Emergency treatment strategy. ERT has been available for the treatment of Fabry disease since 2001. U.S Food and Drug Administration has approved the ERT for the treatment of Fabry disease. ERT comforts the pain, decreases the lipid storage and preserves organ function in patients with this disorder. Alternative therapy involves palliative and supportive approach for the treatment of Fabry disease. Emergency treatment strategy involves administration of small molecule drugs which are very effective and have a quick response.
The Fabry disease market presents an enormous opportunity in its treatment and cure. The driving factors those have been aiding the growth of The Global Fabry Disease Market. Firstly, there are provision for orphan drugs, diseases with restricted patient population, such as Fabry disease have limited approved drugs. Special benefits are given to this drugs like few years of market exclusivity, tax benefits for clinical testing and exclusion from prescription drug fees in order to recover the research and development expenses of the drug.
Secondly, use of tools like ICD, it is a standard tool for diagnosis purposes. These codes are used for reimbursements by the private organizations or government insurers. The code for Fabry disease is E75.21 ICD-10-CM code. ICD-10 codes have been designed to provide superior specificity and better clinical details. ICD-10-CM codes are also expected to provide complete healthcare data, thus helping in the development of advanced clinical pathways and disease protocols. However, currently there is a lack of disease-modifying therapy in the Fabry disease market but there are lot of potential for the improvement in near future.
Some of the key players in this market are Genzyme Corporation, Shire plc. Amicus Therapeutics. Inc., Synageva BioPharma Corp., JCR Pharmaceutical, ISU ABXIS Co. Ltd., Protalix BioTherapeutics, and Neuraltus Pharmaceuticals, Inc., Biosidus.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.